Production (Stage)
RAMM Pharma Corp.
RAMM
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.95M | 3.19M | 3.19M | 3.29M | 3.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.95M | 3.19M | 3.19M | 3.29M | 3.40M |
| Cost of Revenue | 1.85M | 1.92M | 1.89M | 2.89M | 3.19M |
| Gross Profit | 1.10M | 1.28M | 1.30M | 401.80K | 213.60K |
| SG&A Expenses | 6.62M | 7.52M | 7.78M | 5.33M | 5.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 84.90K | 86.30K | 89.10K | 95.40K | 101.30K |
| Total Operating Expenses | 8.56M | 9.53M | 9.76M | 8.31M | 8.66M |
| Operating Income | -5.61M | -6.33M | -6.56M | -5.03M | -5.26M |
| Income Before Tax | -9.99M | -11.19M | -12.10M | -6.53M | -6.58M |
| Income Tax Expenses | 9.10K | -56.90K | 5.90K | 7.10K | 7.10K |
| Earnings from Continuing Operations | -10.00 | -11.13 | -12.11 | -6.54 | -6.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.00M | -11.13M | -12.11M | -6.54M | -6.59M |
| EBIT | -5.61M | -6.33M | -6.56M | -5.03M | -5.26M |
| EBITDA | -5.01M | -5.63M | -5.76M | -4.27M | -4.42M |
| EPS Basic | -0.08 | -0.09 | -0.10 | -0.05 | -0.06 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.08 | -0.09 | -0.10 | -0.05 | -0.06 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 477.56M | 477.56M | 477.56M | 477.53M | 478.82M |
| Average Diluted Shares Outstanding | 477.56M | 477.56M | 477.56M | 477.53M | 478.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |